Adenoviral Vectors as Experimental and Therapeutic Tools

  • Anthony Rosenzweig
  • Takashi Matsui
Part of the Progress in Experimental Cardiology book series (PREC, volume 1)


Adenoviral-mediated gene transfer to the cardiovascular system is of interest both for gene therapy applications and for the development of genetic overexpression models for pathophysiologic studies in vitro and in vivo. Recombinant adenoviral vectors (Ad) are particularly appealing tools for gene transfer to the cardiovascular system because of their high efficiency and ability to transduce nonreplicating cells, such as vascular endothelial and smooth muscle cells, as well as cardiocytes in vitro and in vivo. The disadvantages of these vectors currently limit their clinical application and include the transience of expression and the immune response they evoke. Efforts are underway in many laboratories to improve the adenoviral vector system by deleting immunogenic viral genes or by combining gene transfer with transient immunosuppression. In the meantime, however, the ability of current adenoviral vectors to transduce cardiovascular cells and tissues can be exploited to help elucidate the role of specific molecules in the pathophysiology of cardiovascular diseases. In this way, appropriate molecular strategies can be developed for use as improved vectors become available. In addtion, such experiments can also advance efforts toward human gene therapy by providing insights into vector-host interactions, which can help guide vector development.


Gene Transfer Adenoviral Vector Recombinant Adenovirus Helper Virus Adenoviral Gene Transfer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Akli S, Caillaud C, Vigne E, Stratford-Perricaudet LD, Poenaru L, Perricaudet M, Kahn A, Peschanski MR. 1993. Transfer of a foreign gene into the brain using adenovirus vectors. Nature Genet 3:224–228.PubMedCrossRefGoogle Scholar
  2. 2.
    Berkner KL. 1988. Development of adenovirus vectors for the expression of heterologous genes. Biotechniques 6:616–629.PubMedGoogle Scholar
  3. 3.
    Jaffe HA, Dane1 C, Longenecker G, Metzger M, Setoguchi Y, Rosenfeld MA, Gant TW, Thorgeirsson SS, Stradord-Perricaudet LD, Perricaudet M, et al. 1992. Adenovirus-mediated in vivo gene transfer and expression in normal rat liver. Nature Genet 1:372–378.PubMedCrossRefGoogle Scholar
  4. 4.
    Le Gal La Salle G, Robert JJ, Berrard S, Ridoux X, Stratford-Perricaudet LD, Perricaudet M, Mallet J. 1993. An adenovirus vector for gene transfer into neurons and glia in the brain. Science 259:988–990.PubMedCrossRefGoogle Scholar
  5. 5.
    Lee SW, Trapnell BC, Rade JJ, Virmani R, Dichek DA. 1993. In vivo adenoviral vector-mediated gene transfer into balloon-injured rat carotid arteries. Circ Res 73:797–807.PubMedGoogle Scholar
  6. 6.
    Lemarchand P, Jones M, Yamda I, Crystal RG. 1993. In vivo gene transfer and expression in normal uninjured blood vessels using replication-deficient recombinant adenovirus vectors. Circ Res 72:1132–1138.PubMedGoogle Scholar
  7. 7.
    WiIlard JE, Landau C, Glamann DB, Burns D, Jessen ME, Pirwitz MJ, Gerard RD, Meidell RS. 1994. Genetic modification of the vessel wall: comparison of surgical and catheter-based techniques for delivery of recombinant adenovirus. Circulation 89:2190–2197.Google Scholar
  8. 8.
    Guzman RJ, Lemarchand P, Crystal RG, Epstein SE, Finkel T. 1993. Efficient gene transfer into myocardium by direct injection of adenovirus vectors. Circ Res 73:1202–1207.PubMedGoogle Scholar
  9. 9.
    Stratford-Perricaudet LD, Makeh I, Perricaudet M, Briand P. 1992. Widespread long-term gene transfer to mouse skeletal muscles and heart. J Clin Invest 90:626–630.PubMedGoogle Scholar
  10. 10.
    Jones N, Shenk T. 1979. An adenovirus type 5 early gene function regulates expression of other early viral genes. Proc Natl Acad Sci USA 76:3665–3669.PubMedCrossRefGoogle Scholar
  11. 11.
    Jones N, Shenk T. 1979. Isolation of adenovirus type 5 host range deletion mutants defective for transformation of rat embryo cells. Cell 17:683–689.PubMedCrossRefGoogle Scholar
  12. 12.
    Shenk T, Jones N, Colby W, Fowlkes D. 1980. Functional analysis of adenovirus-5 host-range deletion mutants defective for transformation of rat embryo cells. Cold Spring Harb Symp Quant Biol 1:367–375.Google Scholar
  13. 13.
    Galos RS, Williams J, Shenk T, Jones N. 1980. Physical location of host-range mutations of adenovirus type 5; deletion and marker-rescue mapping. Virology 104:510–513.PubMedCrossRefGoogle Scholar
  14. 14.
    Graham FL, Prevec L. 1991. Manipulation of adenovirus vectors. In Murray EJ (ed), Gene Transfer and Expression Protocols, vol. 7. Clifton, NJ: Humana Press, pp. 109–128.CrossRefGoogle Scholar
  15. 15.
    Graham FL. 1987. Growth of 293 cells in suspension culture. J Gen Virol 68:937–940.PubMedGoogle Scholar
  16. 16.
    Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM. 1994. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 91:4407–4411.PubMedCrossRefGoogle Scholar
  17. 17.
    Yang Y, Ertl HC, Wilson JM. 1994. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1:433–442.PubMedCrossRefGoogle Scholar
  18. 18.
    Yang Y, Xiang Z, Ertl HC, Wilson JM. 1995. Upregulation of class I major histocompatibility complex antigens by interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo. Proc Natl Acad Sci USA 92:7257–7261.PubMedCrossRefGoogle Scholar
  19. 19.
    Yang Y, Wilson JM. 1995. Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLs in vivo. J Immunol 155:2564–2570.PubMedGoogle Scholar
  20. 20.
    Newman KD, Dunn PF, Owens JW, Schulick AH, Virmani R, Sukhova G, Libby P, Dichek DA. 1995. Adenovirus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia. J Clin Invest 96:2955–2965.PubMedCrossRefGoogle Scholar
  21. 21.
    Barr D, Tubb J, Ferguson D, Scaria A, Lieber A, Wilson C, Perkins J, Kay MA. 1995. Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains. Gene Ther 2:151–155.PubMedGoogle Scholar
  22. 22.
    Yang Y, Nunes FA, Berencsi K, Gonczol E, Engelhardt JF, Wilson JM. 1994. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nature Genet 7:362–369.PubMedCrossRefGoogle Scholar
  23. 23.
    Engelhardt JF, Ye X, Doranz B, Wilson JM. 1994. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA 91:6196–6200.PubMedCrossRefGoogle Scholar
  24. 24.
    Engelhardt JF, Litzky L, Wilson JM. 1994. Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2a. Human Gene Ther 5:1217–1229.Google Scholar
  25. 25.
    Gerszten R, Luscinskas F, Ding H, et al. In press. Adhesion of memory lymphocytes to VCAM-1-transduced human vascular endothelial cells under simulated physiological flow conditions in vitro. Circ Res.Google Scholar
  26. 26.
    Stemme S, Holm J, Hansson GK. 1992. T lymphocytes in human atherosclerotic plaques are memory cells expressing CD45RO and the integrin VLA-1. Arterioscler Thromb 12:206–211.PubMedGoogle Scholar
  27. 27.
    Hajjar R, Kang J, Gwathmey J, Rosenzweig A. In press. Physiological effects of adenoviral gene transfer of sarcoplasmic reticulum calcium ATPase in isolated rat myocytes. Circulation.Google Scholar
  28. 28.
    Guzman RJ, Hirschowitz EA, Brody SL, Crystal RG, Epstein SE, Finkel T. 1994. In vivo suppression of injury-induced vascular smooth muscle cell accumulation using adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene. Proc Natl Acad Sci USA 91:10732–10736.PubMedCrossRefGoogle Scholar
  29. 29.
    Chang MW, Barr E, Seltzer J, Jiang YQ, Nabel GJ, Parmacek MS, Leiden JM. 1995. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active from of the retinoblastoma gene product. Science 267:518–522.PubMedCrossRefGoogle Scholar
  30. 30.
    Quinones MJ, Leor J, Kloner RA, Ito M, Patterson M, Witke WF, Kedes L. 1996. Avoidance of immune response prolongs expression of genes delivered to the adult rat myocardium by replication-defective adenovirus. Circulation 94:1394–1401.PubMedGoogle Scholar
  31. 31.
    Kay MA, Holterman AX, Meuse L, Gown A, Ochs HD, Linley PS, Wilson CB. 1995. Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration. Nature Genet 11:191–197.PubMedCrossRefGoogle Scholar
  32. 32.
    Fisher KJ, Choi H, Burda J, Chen SJ, Wilson JM. 1996. Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology 217:11–22.PubMedCrossRefGoogle Scholar
  33. 33.
    Curiel DT, Agarwal S, Wagner E, Cotten M. 1991. Adenovirus enhancement of transferrin-polylysine-mediated gene delivery. Proc Natl Acad Sci USA 88:8850–8854.PubMedCrossRefGoogle Scholar
  34. 34.
    Curiel DT. 1994. High-efficiency gene transfer employing adenovirus-polylysine-DNA complexes. Nat Immunity 13:141–164.Google Scholar

Copyright information

© Kluwer Academic Publishers 1998

Authors and Affiliations

  • Anthony Rosenzweig
    • 1
  • Takashi Matsui
    • 1
  1. 1.Massachusetts General HospitalUSA

Personalised recommendations